{"id":"NCT03409744","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia","officialTitle":"An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-13","primaryCompletion":"2023-04-13","completion":"2023-04-13","firstPosted":"2018-01-24","resultsPosted":"2024-04-30","lastUpdate":"2025-04-08"},"enrollment":116,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Homozygous Familial Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"evinacumab","otherNames":["REGN1500","EVKEEZAÂ®"]}],"arms":[{"label":"evinacumab","type":"EXPERIMENTAL"}],"summary":"The primary objectives of the study are:\n\n* To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH)\n* To evaluate the long-term safety and tolerability of evinacumab in adolescent patients with HoFH\n\nThe secondary objectives of the study are:\n\n* To evaluate the effect of evinacumab on lipid parameters in patients with HoFH\n* To evaluate the effect of evinacumab on lipid parameters in adolescent patients with HoFH\n* To evaluate the potential development of anti-evinacumab antibodies","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216","timeFrame":"Up to 216 weeks","effectByArm":[{"arm":"Overall Study Total Evinacumab","deltaMin":93,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["United States","Australia","Austria","Canada","Czechia","France","Greece","Italy","Japan","Netherlands","South Africa","Ukraine"]},"refs":{"pmids":[],"seeAlso":["https://www.trialsummaries.com/"]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":116},"commonTop":["Nasopharyngitis","COVID-19","Headache","Influenza like illness","Arthralgia"]}}